Video-assisted thoracoscopic surgery

Closure Devices Lead Sternal Closure Systems Market: Innovations in Surgical Techniques Boost Adoption - ResearchAndMarkets.com

Retrieved on: 
Vendredi, novembre 10, 2023
Surgery, Health, Prevalence, Circulatory system, Patient, Cardiovascular disease, Heart failure, Coronary artery disease, Compound annual growth rate, Sternum, Vascular closure device, Ageing, Trauma, Growth, Video-assisted thoracoscopic surgery, Video game, Dentistry, Health insurance

These systems play a vital role in the closure and stabilization of the sternum following open-heart surgery or sternotomy.

Key Points: 
  • These systems play a vital role in the closure and stabilization of the sternum following open-heart surgery or sternotomy.
  • As these diseases become more common, there is a rising demand for sternal closure systems.
  • Advancements in Surgical Techniques: Innovations in surgical techniques, including minimally invasive cardiac surgeries, have led to a growing need for specialized sternal closure systems that offer stability, reduced trauma, and enhanced patient outcomes.
  • Closure Devices Dominate the Market: Closure devices, including rigid plate systems, wire cerclage systems, and interlocking systems, generated the highest revenue in the sternal closure systems market in 2022.

MARKETVUE® REPORT: Surgery remains the only option for the ~50% of LQTS patients refractory or intolerant to beta blockers

Retrieved on: 
Mardi, novembre 7, 2023
Long QT syndrome, Libido, ICD, Physician, Video-assisted thoracoscopic surgery, REACH, Risk, Perforation, LQTS, Depression, Subcutaneous Implantable Defibrillator (S-ICD), LCSD, Patient, Fatigue, Pharmaceutical industry

NEWTON, Mass., Nov. 7, 2023 /PRNewswire/ -- Long QT syndrome (LQTS) is a rare congenital cardiac arrhythmia characterized by a prolonged recovery in cardiac action potential that can cause deadly arrhythmias.

Key Points: 
  • According to LQTS experts interviewed by REACH , most cases of LQTS, especially LQTS type 1, are well-controlled by the current standard of care—beta blockers—despite less the less-than-ideal side effects they cause (e.g., fatigue, depression, decreased libido).
  • However, for high-risk patients that experience breakthrough events despite maximal tolerated beta blocker treatment, physicians turn to surgical options that include implantable cardioverter-defibrillators (ICDs) or left cardiac sympathetic denervation (LCSD).
  • Additionally, while a large majority of patients are well-managed by beta blockers, up to half of these patients struggle with the side effects and could benefit from a better-tolerated treatment option.
  • A lot of those are my patients with long QT syndrome who have had an ICD since childhood."

Medtronic receives FDA approval for extravascular defibrillator to treat abnormal heart rhythms, sudden cardiac arrest

Retrieved on: 
Lundi, octobre 23, 2023
Conductance quantum, Ventricular tachycardia, Patient, FDA, SCA, EV, NYSE, Food, ICD, Heart, ATP, Trial of the century, Longevity, Vein, Video-assisted thoracoscopic surgery, Kaplan–Meier estimator, Ventricular fibrillation, Risk, The New England Journal of Medicine, Lead, Sternum, Arrhythmia, Safety, Ambient occlusion, Hospital, Food and Drug Administration, Medical imaging, Medical device, Electrophysiology, Medtronic

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest (SCA). The Aurora EV-ICD system is the first-of-its-kind to provide the life-saving benefits of traditional, transvenous ICDs with a lead (thin wire) placed under the breastbone, outside of the heart and veins. The Aurora EV-ICD delivers lifesaving defibrillation, anti-tachycardia pacing (ATP), and back-up (pause-prevention) pacing therapies via a device similar in size, shape, and longevity to traditional, transvenous ICDs.

Key Points: 
  • In the coming weeks, the Aurora EV-ICD system will be commercially available on a limited basis in the United States.
  • [1] Additionally, 33 defibrillation shocks were avoided1 by having ATP – which paces the heart to interrupt and terminate a dangerous rhythm – programmed "on."
  • Traditional ICDs typically are implanted below the collarbone, with the lead(s) threaded through the veins and into the heart.
  • Boersma, M.D., Ph.D., cardiologist at St. Antonius Hospital, Nieuwegein, The Netherlands, and a limited launch is underway in select European countries.

Abyrx Receives FDA Clearance for MONTAGE® Settable Bone Putty for Use in Cardiothoracic Surgery

Retrieved on: 
Mardi, septembre 26, 2023
Ankle, Video-assisted thoracoscopic surgery, Partnership, Surgeon, University, Bleeding, Sternum, NCT, University of Calgary, Elective surgery, Libin Cardiovascular Institute, Anatomy, Foot, Bone wax, The Journal of Thoracic and Cardiovascular Surgery, Pain, Journal, MD, Patient, Nightfall and Other Stories, FDA, Trauma, Sports medicine, Safety, Flowable, Pharmaceutical industry, Dentistry, Medical device

STAMFORD, Conn., Sept. 26, 2023 /PRNewswire/ -- Abyrx, Inc. (http://abyrx.com), a leading biomaterial sciences company with a focus on therapeutic technologies for use during surgical procedures, today announced that the United States Food and Drug Administration (FDA) has provided regulatory clearance for the company's MONTAGE® Settable Bone Putty for use in cardiothoracic surgery following sternotomy. This represents the first time that the FDA has granted clearance for the use of a settable bone putty on the sternum, and it follows previous FDA clearances for MONTAGE as a bone void filler, cranial cement, and hemostatic bone putty.

Key Points: 
  • This represents the first time that the FDA has granted clearance for the use of a settable bone putty on the sternum, and it follows previous FDA clearances for MONTAGE as a bone void filler, cranial cement, and hemostatic bone putty.
  • MONTAGE is unique as a moldable putty that adheres to bleeding bone and rapidly hardens to achieve bone-like properties after application.
  • Upon application, MONTAGE controls bleeding and eliminates the need for topical agents known to prevent bone healing, such as bone wax.
  • For over a decade, Dr. Fedak has championed enhanced sternal closure using settable biomaterials to accelerate patient recovery after open heart surgery.

New pulmonary valve benefits quality, length of life

Retrieved on: 
Mardi, août 8, 2023
Video-assisted thoracoscopic surgery, Communication, Sternum, Bed, Nursing, Quality of life, Sister, Multimedia, OSF HealthCare, Thoracic cavity, Walking, Hospital, MD, Patient, OSF, Risk, Missionary, Pediatrics, Pulmonary valve, Third order, FDA, Groin, Butterfly valve, Health insurance, Medical device, Dentistry, Alterra

The FDA-approved valve consists of a catheter-based stent (called Alterra), an artificial heart valve (SAPIEN 3) and the opportunity to implant the stent and valve without the need for open-heart surgery.

Key Points: 
  • The FDA-approved valve consists of a catheter-based stent (called Alterra), an artificial heart valve (SAPIEN 3) and the opportunity to implant the stent and valve without the need for open-heart surgery.
  • She says this new technology will expand peoples' lives and enhance their quality of life.
  • This current pulmonary valve that is in place allows you to be ready for another less-invasive procedure when the time comes.
  • Dr. Patel and her team administered four pulmonary valves in patients this spring, with two more procedures planned in August.

Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+™ Hemostatic Device Usage in Cardiac Surgical Procedures

Retrieved on: 
Mardi, août 1, 2023
Video-assisted thoracoscopic surgery, Bleeding, Regulation of tobacco by the U.S. Food and Drug Administration, TFX, The Journal of Thoracic and Cardiovascular Surgery, Elective surgery, Journal, Hemostasis, Patient, IDE, FDA, NYSE, Safety, Medical device, Dentistry, Teleflex, Anesthesia, QuikClot

This allows clinicians to use the QuikClot Control+™ Device to control all bleeding in cardiac surgical procedures.

Key Points: 
  • This allows clinicians to use the QuikClot Control+™ Device to control all bleeding in cardiac surgical procedures.
  • The expanded indications enable device utilization across a wider patient population and breadth of surgical procedures.
  • The QuikClot Control+™ Hemostatic Device also received expanded intended uses to include use with patients on anticoagulation/antiplatelet medication, use with or without autotransfusion (blood salvage) equipment, and use with or without cardiopulmonary bypass systems.
  • “We look forward to supporting positive patient outcomes in these procedures through the expanded use potential of our QuikClot Control+™ Devices.”

The Worldwide Facial Aesthetics Industry is Expected to Reach $15.2 Billion by 2028 at a 14.5% CAGR - ResearchAndMarkets.com

Retrieved on: 
Mardi, janvier 31, 2023
Cosmetics, Retail, Health, Surgery, Filler (animal food), Video-assisted thoracoscopic surgery, Woman, Moles, Acne, Life expectancy, Pigment, Diagnosis, United Nations, Face, Skin, Ageing, Neck, Forehead, Paralysis, Application, Growth, Facial muscles, Surgeon, Dermis, Injectable filler, Tissue paper, Dentistry, Chemical substance

The Global Facial Aesthetics Market size is expected to reach $15.2 billion by 2028, rising at a market growth of 14.5% CAGR during the forecast period.

Key Points: 
  • The Global Facial Aesthetics Market size is expected to reach $15.2 billion by 2028, rising at a market growth of 14.5% CAGR during the forecast period.
  • Facial aesthetics, also known as facial cosmetic surgeries, are non-surgical operations intended to reduce the appearance of age-related changes in the skin.
  • Dermal fillers and Botox injections are the most common type of ailments used in facial aesthetics.
  • Non-surgical cosmetic procedures that draw attention to a patient's characteristics and enhance their natural beauty are included in facial aesthetics.

Medtronic Receives CE Mark for Extravascular Defibrillator System That Treats Abnormal Heart Rhythms

Retrieved on: 
Vendredi, février 17, 2023
Aurora, Video-assisted thoracoscopic surgery, Physician, Kaplan–Meier estimator, Lead, Arrest, Hospital, Vein, Patient, Safety, NYSE, European Society of Cardiology, Cardiac arrest, SCA, ATP, Ventricular fibrillation, The New England Journal of Medicine, Signal enhancement by extravascular water protons, Risk, ESC, Ambient occlusion, ICD, Death, EV, Heart, Ventricular tachycardia, Conductance quantum, Pivotal, University of Amsterdam, Sternum, Longevity, Medical device, Medical imaging, Medtronic, Cardiology

DUBLIN, Feb. 17, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT) has received CE (Conformité Européenne) Mark for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest. The Aurora EV-ICD system provides the life-saving benefits of traditional ICDs while avoiding certain risks because its lead (thin wire) is placed outside the heart and veins. The Aurora EV-ICD system is investigational in the United States.

Key Points: 
  • The Aurora EV-ICD system provides the life-saving benefits of traditional ICDs while avoiding certain risks because its lead (thin wire) is placed outside the heart and veins.
  • The Aurora EV-ICD system is expected to be commercially available in autumn 2023 in select countries in Europe.
  • There were no major intraprocedural complications, nor any unique complications observed related to the EV-ICD procedure or system.
  • "This approval is a significant milestone in achieving our goal of delivering a defibrillation solution that treats sudden cardiac arrest while improving the patient experience."